Lineage Cell Therapeutics, Inc.

AMEX:LCTX

Biotechnology

Healthcare
$0.82 -2.80%

-$0.04 today

Market cap
$206.36M
Beta
1.51
P/E (TTM)
-4.6
EPS (TTM)
-$0.26
52W Low $0.85High $2.09

Volume 6.78M

Average 1.19M

Returns on capital

Lineage Cell Therapeutics, Inc. management

Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.

Return Metrics

ROE, ROIC & ROA over time

Management
Older years hidden. Sign in to unlock

ROE

-142.6%

avg -47.5%

ROIC

-19.7%

avg -32.5%

ROA

-56.4%

avg -22.9%

Analysis

ROIC is currently the strongest return metric at -19.7% versus its period average of -32.5%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.

Leadership

Who runs the company?

Review the executive team, tenure, compensation, and ownership.

Management

Key executives, compensation & ownership

NameTitleCompensationAgeShares OwnedOwnership %

Brian Culley

Chief Executive Officer, President & DirectorUSD 1.23M55——

Jill Ann Howe

Chief Financial OfficerUSD 718K501.05M0.42%

George A. Samuel

General Counsel & Company SecretaryUSD 690.3K45——

Harold D. Waitz

Vice President of Regulatory Affairs & Quality ControlUSD 90K840<0.01%

Alexandra Hernandez

Senior Director of Finance & Controller——29.19K0.01%

Charlotte Hubbert

Vice President of Corporate Strategy & Development————

Priyantha Herath

Senior VP & Head of Clinical Operations————

Rami Skaliter

Chief Executive Officer of Cell Cure Neurosciences—68——

Ioana C. Hone

Director of Investor Relations————

Compensation is shown in the reported currency; data updated Nov 7, 2026.

Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Mar 5, 2026.

Insider trading

Are insiders buying or selling?

Follow recent insider purchases and sales reported on Form 4.

Insider Trading

SEC Form 4 transactions — last 12 months

Buys

1

$24,375.00

Sells

0

$0.00

Net Transaction Value

+$24,375.00

Net buying

Most Active

Culley Brian M

1 transactions

Transactions sorted by date, descending.

Open-market insider purchases and sales reported during the last 12 months
Type
Mar 12, 26

Culley Brian M

Direct

Buy$24.4K

Summary

Insiders reported 1 buys worth $24,375.00 and 0 sells worth $0.00 over the last 12 months. That adds up to net buying of $24,375.00. Culley Brian M was the most active insider with 1 transactions.

Growth analysis

Is management growing the business?

Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.

Growth Analysis

Historical CAGR & forward analyst estimates

Metric 10yr 5yr3yr Fwd Est.
EPSN/AN/AN/A
N/A2 analysts
RevenueN/AN/A-0.3%
+103.3% (5yr)3 analysts
Net IncomeN/AN/AN/A
N/A3 analysts
EBITN/AN/AN/A
N/A3 analysts

Analysis

Recent growth has been strongest in Revenue at -0.3% over three years. Forward estimates point to Revenue at +103.3% (5yr), giving you a quick check on whether expectations are accelerating or cooling.

Competitors

Who does Lineage Cell Therapeutics, Inc. compete with?

Open similar companies to compare how their management teams allocate capital.

Questions

Management questions

Common questions about LCTX's management, answered from reported figures.

Who manages LCTX?

Lineage Cell Therapeutics, Inc. (LCTX) lists 9 active executives. The top listed executive is Alexandra Hernandez, Senior Director of Finance & Controller.

Are LCTX insiders buying or selling?

Recent insider activity shows net buying of $45.36M.